Study of XNW34017 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called XNW34017 for people with advanced solid tumors, including small cell lung cancer and prostate cancer. It may be an option if you've tried other treatments that no longer work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced cancer that has spread and standard treatments have stopped working.
- You must be able to do most daily activities on your own (ECOG performance status 0 or 1).
- Your blood tests show good kidney and liver function, and healthy blood cell counts.
- You cannot have certain heart conditions or major bleeding risks.
- If you are a woman able to have children, you must have a negative pregnancy test and use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called XNW28012 for people with advanced solid tumors that have not responded to or caused side effects from standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
This trial tests a new drug called XNW29016 for people with advanced cancer that has stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This study tests a new oral drug called XNW5004 in combination with other standard treatments (like abiraterone, enzalutamide, or chemotherapy) for advanced prostate cancer that has spread and is no longer controlled by hormone therapy alone. The goal is to see if these combinations work better than current options.
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.